MDNA Life Sciences Agrees Licensing Deal with Aspire Pharma Ltd for the Mitomic® Prostate Test in the UK

MDNA Life Sciences Inc. (MDNA), the molecular diagnostics company revolutionizing the development of liquid biopsy biomarkers based on the mitochondrial genome, announced today that it has agreed a licensing deal with Aspire Pharma Ltd. (Aspire) in the UK for the Mitomic® Prostate Test (MPT™). On the heels of recent news that MDNA’s CE marked MPT™ Real-Time PCR kit is now commercially available, this is the first international partner to be announced by MDNA and is the start of the global roll-out of MPT™through a growing network of distribution partners.